Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company whose news flow centers on the development of its INTASYL® gene silencing technology and lead compound PH-762. Company announcements describe INTASYL as a gene silencing platform focused on immuno-oncology therapeutics, with PH-762 targeting the PD-1 gene implicated in various forms of skin cancer.
News about Phio frequently covers clinical trial milestones for PH-762. The company has reported completion of enrollment in its ongoing Phase 1b dose escalation trial (NCT 06014086), interim pathology results in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and safety reviews by its Safety Monitoring Committee. Updates have included detailed response rates, such as complete, near complete, and partial responses based on tumor clearance, as well as statements that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed in the cohorts reported.
Phio also issues regulatory and development updates, including acceptance by the U.S. Food and Drug Administration of its nonclinical protocol study design for a toxicology study required before a pivotal trial of PH-762. Additional news items describe agreements with a U.S. manufacturer for cGMP clinical supply of PH-762 and progress toward delivering commercially viable drug product.
Investors following PHIO news will also see financing and corporate announcements, such as warrant inducement transactions, cash runway commentary, and board-level changes, including the appointment of a Lead Independent Director. The company regularly participates in investor conferences and scientific meetings, where it presents INTASYL technology and PH-762 data, and has highlighted external recognition such as PH-762 being named “Immunomodulatory Solution of the Year” in the BioTech Breakthrough Awards.
This news page aggregates these clinical, regulatory, financing, and governance updates so readers can track how Phio’s INTASYL platform and PH-762 program are progressing over time.
Phio Pharmaceuticals (NASDAQ: PHIO) reported positive results from the third cohort of its Phase 1b clinical trial for PH-762, a skin cancer treatment. Two out of three patients with cutaneous squamous cell carcinoma (cSCC) achieved complete pathologic response (100% tumor clearance), while one patient showed non-response. Across all three cohorts, involving 10 patients total (9 cSCC, 1 melanoma), 4 cSCC patients achieved complete response, one showed near-complete response (>90%), and one had partial response (>50%).
The trial evaluates PH-762's safety and tolerability in various skin cancer stages. Notably, no dose-limiting toxicities or significant adverse effects were observed, with the treatment being well-tolerated across all dose cohorts. The fourth cohort is currently enrolling, with trial completion expected in Q3 2025.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. CEO and Chairman Robert Bitterman will present on May 7, 2025, at 2:00 pm EST, providing updates on the company's proprietary INTASYL gene silencing technology and progress on the ongoing clinical trial of PH-762 for skin cancer treatment. The presentation will include a live Q&A session, with a replay available on Renmark Financial Communications' website.
Phio Pharmaceuticals (NASDAQ: PHIO) announced positive safety results for the third cohort in its Phase 1b clinical trial of PH-762, their lead INTASYL® siRNA compound for skin cancer treatment. The Safety Monitoring Committee recommended advancing to the fourth dose escalation cohort following successful results in three cutaneous squamous cell carcinoma patients, who showed no serious adverse events or dose-limiting toxicities.
The multi-center trial (NCT 06014086) evaluates PH-762's safety and tolerability in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Prior results from cohorts 1 and 2, comprising seven patients, showed promising outcomes. In the second cohort, two patients achieved complete response (100% tumor clearance) and one patient showed partial response (90% clearance) by Day 36. All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.
Phio Pharmaceuticals (NASDAQ: PHIO) announced two podium presentations at the 11th Annual Immunotherapy of Cancer Conference in Munich, Germany on April 3, 2025. The presentations focus on their lead INTASYL siRNA product candidates:
1. PH-762: An INTASYL siRNA compound targeting PD-1, currently in clinical trials (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies. The therapy has shown promising preclinical efficacy and favorable tolerability.
2. PH-894: An INTASYL siRNA compound that selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, aimed at improving adoptive cell therapy.
The presentations will be delivered by Melissa Maxwell, Phio's Director of Research and Program Management, in Plenary Sessions 3 and 11 on April 3rd and 5th, 2025, respectively.
Phio Pharmaceuticals (NASDAQ: PHIO) reported its 2024 financial results and provided updates on its PH-762 clinical trial progress. The company's Phase 1b trial for PH-762, treating cutaneous carcinomas through intratumoral injection, showed promising results with 2 complete responses and 1 partial response in the second cohort. The third cohort is fully enrolled, with study completion expected in Q3 2025.
Financial highlights include raising $9.2 million through offerings and $2.9 million from warrant exercises. The company reported cash position of $5.4 million as of December 31, 2024, with net loss decreasing to $7.2 million ($9.08 per share) from $10.8 million in 2023. Research and development expenses decreased by 42% to $2.7 million, while general and administrative expenses reduced by 14% to $3.7 million.
The company implemented cost rationalization measures, including relocating to a smaller facility and terminating its Clinical Co-Development Agreement with AgonOx. Phio's patent portfolio includes 77 issued patents, with 69 covering its INTASYL technology.
Phio Pharmaceuticals (NASDAQ: PHIO) presented interim results from its Phase 1b clinical study of PH-762 at the American Academy of Dermatology's Late-Breaking Research session. The study evaluates the safety and tolerability of intratumoral PH-762 in cutaneous carcinomas.
In the second dose cohort of four patients, two patients with cutaneous squamous cell carcinoma (cSCC) achieved complete response (100% pathological cure), one achieved partial response (90% pathological cure), and one showed stable disease. The study has completed required safety enrollment for its third dose cohort, with the fourth dose cohort screening planned for early April.
PH-762 utilizes INTASYL® siRNA gene silencing technology to enhance immune cells' effectiveness in killing cancer cells. The research focuses on cSCC, melanoma, and Merkel cell carcinoma, with stages 1 and 2 cSCC representing 77% of all new cSCC cases annually.
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the third safety cohort in its Phase 1b dose-escalation clinical trial of PH-762. The study (NCT 06014086) is evaluating the intratumoral administration of PH-762 as a neoadjuvant treatment for various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
The multi-center trial aims to assess safety, tolerability, and tumor response while determining the recommended dose for future studies. The company utilizes its proprietary INTASYL® siRNA gene silencing technology to enhance the effectiveness of immune cells in targeting cancer cells. Phio plans to begin screening for the fourth dose cohort in early April 2025.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event will feature CEO and Chairman Robert Bitterman presenting the company's proprietary INTASYL siRNA technology and ongoing clinical trial of PH-762 for skin cancer treatment.
The presentation and live Q&A session is scheduled for March 5, 2025, at 12:00 pm EST. The virtual event will be accessible to stakeholders, investors, and interested parties, with a replay available on the Renmark Financial Communications website.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company developing INTASYL® siRNA gene silencing technology for cancer treatment, has appointed David H. Deming to its Board of Directors effective February 19, 2025. Deming will serve on the Board's Nominating Committee, bringing the total board membership to 6 directors, with 5 being independent.
Deming brings over 30 years of experience in investment banking and asset management, including 27 years at JP Morgan where he led the Health Group in investment banking for 12 years. He later joined Integrated Finance , where he developed the SmartNest 401(k) asset allocation product, which was subsequently acquired by Dimensional Fund Advisors in 2010.
Phio Pharmaceuticals (NASDAQ: PHIO) announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company's CEO and Chairman, Robert Bitterman, will present on February 4, 2025, at 2:00 pm EST, discussing their INTASYL siRNA technology and ongoing clinical trial of PH-762 for skin cancer treatment.
The presentation will include a live Q&A session, with a replay available on Renmark Financial Communications' website. Phio is a clinical-stage biotechnology company developing therapeutics using their INTASYL siRNA gene silencing technology, aimed at enhancing immune cells' effectiveness in fighting cancer cells.